Arbutus Biopharma Corporation · NASDAQ:ABUS

Arbutus Biopharma — Investor Presentation (May 2022)

32 slides from Arbutus Biopharma's investor presentation, May 5, 2022

  1. Slide 1: Corporate Presentation

    May 5, 2022 NASDAQ: ABUS www.arbutusbio.com Corporate Presentation

  2. Slide 2: Forward-Looking Statements

    NASDAQ: ABUS www.arbutusbio.com Forward - Looking Statements 2 This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified

  3. Slide 3: Investment Highlights

    NASDAQ: ABUS www.arbutusbio.com Investment Highlights 3 HCV: Hepatitis C Virus | HIV Human Immunodeficiency Virus Significant Unmet Medical Need in HBV Undetectable HBV DNA and HBsAg delivered through finite duration treatment with a combination of drugs with different modes of action Goal of HBV Fu

  4. Slide 4: Proven Leadership Team

    NASDAQ: ABUS www.arbutusbio.com NASDAQ: ABUS www.arbutusbio.com Proven Leadership Team 4 Successful track records in the discovery, development, and commercialization of multiple antivirals including sofosbuvir, etravirine, rilpivirine , telaprevir and simeprevir William H. Collier Chief Development

  5. Slide 5: Broad Pipeline

    NASDAQ: ABUS www.arbutusbio.com Broad Pipeline 5 HBV AB - 729 - 001 single - ascending dose / multiple - ascending dose RNAi Therapeutic AB - 729 AB - 729 - 201 Combo trial (AB - 729 + Peg - IFNa - 2a + NA) Combo trial (AB - 729 + core inhibitor + NA) AB - 729 - 202 Combo trial (AB - 729 + vaccine +

  6. Slide 6: HBV Presents a Significant Unmet Medical Need

    NASDAQ: ABUS www.arbutusbio.com Sources : Hepatitis B Fact Sheet, WHO https://www.who.int/news - room/fact - sheets/detail/hepatitis - b Hep B Foundation link: https://www.hepb.org/what - is - hepatitis - b/what - is - hepb/facts - and - figures/ Kowdley et al. Hepatology (2012) Prevalence of Chroni

  7. Slide 7: Significant Opportunity to Improve HBV Cure Rates

    NASDAQ: ABUS www.arbutusbio.com New HBV Therapies rate of Undetectable HBV DNA rate of HBsAg Loss HIGHER CURES RATES SOC: Standard Of Care | HBsAg : HBV Surface Antigen | PegIFN : P egylated Interferon Source: EASL HBV Clinical Practice Guidelines, 2017 - Pegasys , PEG - Intron, Baraclude and Viread

  8. Slide 8: Compelling Growth Opportunity in the HBV Market

    NASDAQ: ABUS www.arbutusbio.com An HBV curative regimen would substantially increase diagnosis and treatment rates to unlock significant market growth opportunities. diagnosis Compelling Growth Opportunity in the HBV Market 8 10.5% Diagnosed 2.3% Treated Low due to sub - optimal SOC cure rate and as

  9. Slide 9: A Combination of Agents with Complementary MOA is Needed for HBV Cure

    NASDAQ: ABUS www.arbutusbio.com 3 2 1 2 A Combination of Agents with Complementary MOA is Needed for HBV Cure 1. Nucleoside Analogue 2. Capsid Inhibitor 3. RNAi & RNA Destabilizer NASDAQ: ABUS www.arbutusbio.com MOA: Mechanism of Action

  10. Slide 10: 3-Pronged Approach to Therapeutic Success

    NASDAQ: ABUS www.arbutusbio.com 10 Block HBsAg ▪ RNAi ▪ RNA Destabilizer Immuno - modulation ▪ PD - L1 Inhibitor ▪ Interferon ▪ Therapeutic vaccines Leading to an HBV CURE 3 - Pronged Approach to Therapeutic Success MOA: Mechanism of Action | NA: Nucleoside Analogue | HBsAg : HBV Surface Antigen Red

  11. Slide 11: RNAi Therapeutic

    NASDAQ: ABUS www.arbutusbio.com AB - 729 RNAi Therapeutic 11 Proprietary GalNAc - conjugate delivery technology provides liver targeting and enables subcutaneous dosing Single trigger RNAi agent targeting all HBV transcripts Inhibits HBV replication and lowers all HBV antigens Pan - genotypic activi

  12. Slide 12: Phase 1a/1b Clinical Trial

    NASDAQ: ABUS www.arbutusbio.com AB - 729 - 001 Phase 1a/1b Clinical Trial HBV : Hepatitis B Virus | TDF : tenofovir disoproxil fumarate | cHBV: chronic HBV` 12 Part 3: Multiple Doses In cHBV Patients - Ongoing E: 60mg Q4W HBV DNA - F: 60mg Q8W HBV DNA - G: 90mg Q8W + TDF HBV DNA+ I: 90mg Q8W HBV DNA

  13. Slide 13: HBsAg Suppression Maintained Off Treatment

    NASDAQ: ABUS www.arbutusbio.com HBsAg Suppression at levels <100 IU/mL Maintained up to 28 Weeks off AB - 729 Treatment 13 ⱡ patients switched to AB - 729 60 mg Q12W after Week 20 dose *Data presented at AASLD 2021 Individual HBeAg - Individual HBeAg + Cohort E AB - 729 60mg every 4 Wks + HBV DNA -

  14. Slide 14: Reduces HBsAg in both DNA- and DNA+ Patients

    NASDAQ: ABUS www.arbutusbio.com 14 AB - 729 dosed at 90mg Q8W or Q12W Reduces HBsAg in both DNA - and DNA+ Patients Data presented at AASLD 2021 Key Findings: • The magnitude of HBsAg suppression (1.8 - 2.0 log reduction at wk 40) was similar across both dosing intervals • Some patients achieved HBs

  15. Slide 15: Mean Baseline HBsAg Response Similar Regardless of Dose

    NASDAQ: ABUS www.arbutusbio.com Mean (SE) Baseline HBsAg Response Similar Regardless of AB - 729 Dose and Dosing Intervals to Date HBV DNA - HBV DNA+ Visit Cohort E 60mg Q4W ⱡ (n=7) Cohort F 60mg Q8W (n=7) Cohort I 90mg Q8W (n=6) Cohort J 90mg Q12W (n=7) Cohort G 90mg Q8W (n=7) Baseline 3.51 (0.20)

  16. Slide 16: Safety Summary

    NASDAQ: ABUS www.arbutusbio.com AB - 729 - 001 Safety Summary ▪ AB - 729 generally safe and well - tolerated after single and repeat doses ▪ No treatment - related SAEs or discontinuations due to AEs ▪ No treatment - related Grade 3 or 4 AEs * ▪ No treatment - related Grade 3 or 4 laboratory abnorma

  17. Slide 17: Clinical Trial Key Takeaways

    NASDAQ: ABUS www.arbutusbio.com AB - 729 - 001 Clinical Trial Key Takeaways ▪ AB - 729 dosed 60mg every 4 wks and every 8 wks and 90mgs every 8 wks and 12 wks resulted in robust and comparable HBsAg declines ▪ AB - 729 monotherapy (90mg single - dose) resulted in robust HBsAg and HBV DNA declines in

  18. Slide 18: Next Steps – Combine with Different Compounds in Phase 2a

    NASDAQ: ABUS www.arbutusbio.com ▪ Enrollment on - going in a Phase 2a combination trial with ongoing NA therapy and short courses of Peg - IFNα - 2a in cHBV patients ▪ Two Phase 2a proof - of - concept clinical collaborations are on - going or expected to initiate shortly to accelerate key combinati

  19. Slide 19: Phase 2a POC Clinical Trial with NA and Peg-IFNα-2a

    NASDAQ: ABUS www.arbutusbio.com 19 AB - 729 - 201: Phase 2a POC Clinical Trial AB - 729 in combination with ongoing NA therapy and short courses of Peg - IFNα - 2a in c HBV patients Follow - up (24 - weeks) AB - 729 + NA + IFN (n=12) NA + IFN (n=12) AB - 729+NA+IFN (n=8) NA + IFN (n=8) AB - 729 + NA

  20. Slide 20: Clinical Collaboration with Assembly Bio

    NASDAQ: ABUS www.arbutusbio.com NA: Nucleoside Analogue AB - 729 Clinical Collaboration Provides accelerated AB - 729 combination POC with Assembly’s capsid inhibitor and a NA 20 Follow Up (24 - weeks) AB - 729 + vebicorvir + NA AB - 729 + NA vebicorvir + NA Baseline Wk 48 Wk 24 Phase 2 clinical tri

  21. Slide 21: Clinical Collaboration with Vaccitech

    NASDAQ: ABUS www.arbutusbio.com 21 Evaluate safety, pharmacokinetics, immunogenicity and anti - viral activity of triple combination - AB - 729, VTP - 300 and an NA compared to double combinations of AB - 729 with an NA and VTP - 300 with an NA Expected to initiate clinical trial in first half of 20

  22. Slide 22: Strategic Collaboration with Qilu Pharmaceutical

    NASDAQ: ABUS www.arbutusbio.com 22 AB - 729 Strategic Collaboration Goal - to bring AB - 729 to the largest HBV patient population and to tap into one of the largest and most promising healthcare markets worldwide Arbutus has received $40M upfront payment and $15M equity investment, and is eligible

  23. Slide 23: AB-836 Next Generation Capsid Inhibitor

    NASDAQ: ABUS www.arbutusbio.com Novel chemical series differentiated from AB - 506 and other competitor compounds in the Class II capsid inhibitor space Leverages a novel binding site within the core protein dimer - dimer interface Improved intrinsic potency with EC50 < 10 nM Active against NA - res

  24. Slide 24: AB-836: Next Generation Capsid Inhibitor

    NASDAQ: ABUS www.arbutusbio.com AB - 836: Next Generation Capsid Inhibitor HBV DNA / 1 o Mechanism cccDNA Formation / 2 o Mechanism Human Serum Shift Compound HepDE19 ; EC 50 μM Ϳ HBV infected PHH ; EC 50 μM Ϳ HBV infected HepG2 - NTCP - C4 ; EC 50 μM) Core I105T Mutation (EC 50 μM ) HBV infected He

  25. Slide 25: AB-836 Phase 1a/1b Clinical Trial

    NASDAQ: ABUS www.arbutusbio.com AB - 836 - 001 Phase 1a/1b Clinical Trial 25 Dose 4 125 mg Dose 3 75 mg Dose 2 30mg Dose 1 10mg Dose 5 175 mg Cohort A Cohort B Dose 5 FE 125 mg Part 1: Single Ascending Dose In Healthy Subjects Alternating Cohorts A and B n=8/cohort; 6 active: 2 placebo Part 2: Multi

  26. Slide 26: AB-836 Phase 1a/1b Preliminary Data

    NASDAQ: ABUS www.arbutusbio.com Part 3: 50mg and 100mg of AB - 836 once daily for 28 days in patients with cHBV Parts 1 & 2: Single and multi - doses of AB - 836 in healthy subjects AB - 836 Phase 1a/1b Clinical Trial Preliminary Data ▪ Safety: ▪ No deaths or SAEs ▪ 1 subject (50mg once daily) disco

  27. Slide 27: AB-161: Next Generation Oral RNA Destabilizer

    NASDAQ: ABUS www.arbutusbio.com AB - 161: Next Generation Oral RNA Destabilizer We believe this approach offers potential for an oral HBsAg reducing agent and all oral combination therapy Offers a novel mechanism of action to reduce HBsAg and other viral proteins and viral RNA Next generation small

  28. Slide 28: AB-101: Oral PD-L1 Inhibitor for HBV Immune Reactivation

    NASDAQ: ABUS www.arbutusbio.com AB - 101: Oral PD - L1 Inhibitor for HBV Immune Reactivation AB - 101 ▪ Blocks PD - L1/PD1 interaction at sub - nM concentrations ▪ Activates HBV - specific immune responses in T - cells from CHB patients in vitro ▪ Novel MOA identified ▪ Demonstrates a robust checkpo

  29. Slide 29: AB-101: Small-Molecule Oral PD-L1 Inhibitor for HBV

    NASDAQ: ABUS www.arbutusbio.com 29 AB - 101: Small - Molecule Oral PD - L1 Inhibitor for HBV -6 -4 -2 0 0 20 40 60 80 100 Compound (Log μM) % I n t e r n a l i z a t i o n AB-101 Inactive Compound AB - 101 reduces PD - L1 on the surface of human primary myeloid cells CD14+ PBMCs N=3 Donors IC 50 = 1

  30. Slide 30: Coronavirus Strategy

    NASDAQ: ABUS www.arbutusbio.com Coronavirus Strategy Leveraging our proven expertise and capabilities in antiviral drug discovery and development Pan - Coronavirus Focused Long Term Commitment Small Molecule Direct - Acting Antivirals X - Chem/ Proteros Collaboration ▪ Proprietary DEL library screen

  31. Slide 31: 2022 Key Milestones

    NASDAQ: ABUS www.arbutusbio.com 2022 Key Milestones Cash balance of $221.8M as of March 31, 2022, cash runway into Q2 2024 Milestone Anticipated Timing 2022 AB - 836, next generation oral capsid inhibitor: Data from Phase 1a/1b clinical trial in patients with chronic HBV 1H AB - 729, RNAi therapeuti

  32. Slide 32: Thank You

    NASDAQ: ABUS www.ArbutusBio.com Thank You

Arbutus Biopharma — Investor Presentation (May 2022) on 6ix